Adherence to therapies for secondary prevention of cardiovascular disease

a focus on aspirin

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Aim: Suboptimal adherence to medications taken chronically for secondary prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the healthcare system despite the well-established benefits of prevention. We conducted a literature search to examine patient adherence to medications for secondary prevention of CVD—as evaluated by prescription refill data, electronic medication monitors, pill counts, and physiologic markers—to better identify an unmet need for measures to improve patient adherence to these therapies. Methods: English-language articles were obtained from the PubMed database using the following key words or combinations thereof “adherence,” “compliance,” “secondary prevention,” and “cardiovascular disease.” Publications that provided adherence data only for primary prevention, lacked data on medication adherence (e.g., focus on guideline adherence), emphasized quality-of-care outcomes, or focused on outcomes of acute interventions were excluded. Results: Multiple patient-, disease-, and treatment-related factors may contribute to poor adherence to treatment regimens, and therefore, a multifactorial approach will likely be needed to improve compliance with prescribed treatments for CVD. Although no magic bullet exists to assure full adherence, adherence programs coupled with patient counseling and education (inclusive of over-the-counter therapies), along with treatments that are less complex or avoid bothersome adverse effects, are more likely to be associated with successful outcomes. Conclusion: Given the burden of CVD to the community and the healthcare system, nonadherence to CVD-preventative medications such as aspirin remains a substantial area of unmet need and represents a key opportunity for the development of quality-of-care enhancement programs to improve health outcomes in this patient population.

Original languageEnglish (US)
Pages (from-to)415-422
Number of pages8
JournalCardiovascular Therapeutics
Volume34
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Secondary Prevention
Aspirin
Cardiovascular Diseases
Medication Adherence
Quality of Health Care
Patient Compliance
Therapeutics
Delivery of Health Care
Guideline Adherence
Community Health Services
Magic
Patient Education
Primary Prevention
PubMed
Compliance
Prescriptions
Publications
Counseling
Language
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{2870389ec5e0405da7659959f1524df5,
title = "Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin",
abstract = "Aim: Suboptimal adherence to medications taken chronically for secondary prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the healthcare system despite the well-established benefits of prevention. We conducted a literature search to examine patient adherence to medications for secondary prevention of CVD—as evaluated by prescription refill data, electronic medication monitors, pill counts, and physiologic markers—to better identify an unmet need for measures to improve patient adherence to these therapies. Methods: English-language articles were obtained from the PubMed database using the following key words or combinations thereof “adherence,” “compliance,” “secondary prevention,” and “cardiovascular disease.” Publications that provided adherence data only for primary prevention, lacked data on medication adherence (e.g., focus on guideline adherence), emphasized quality-of-care outcomes, or focused on outcomes of acute interventions were excluded. Results: Multiple patient-, disease-, and treatment-related factors may contribute to poor adherence to treatment regimens, and therefore, a multifactorial approach will likely be needed to improve compliance with prescribed treatments for CVD. Although no magic bullet exists to assure full adherence, adherence programs coupled with patient counseling and education (inclusive of over-the-counter therapies), along with treatments that are less complex or avoid bothersome adverse effects, are more likely to be associated with successful outcomes. Conclusion: Given the burden of CVD to the community and the healthcare system, nonadherence to CVD-preventative medications such as aspirin remains a substantial area of unmet need and represents a key opportunity for the development of quality-of-care enhancement programs to improve health outcomes in this patient population.",
author = "Packard, {Kathleen A.} and Hilleman, {Daniel E.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/1755-5922.12211",
language = "English (US)",
volume = "34",
pages = "415--422",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Adherence to therapies for secondary prevention of cardiovascular disease

T2 - a focus on aspirin

AU - Packard, Kathleen A.

AU - Hilleman, Daniel E.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Aim: Suboptimal adherence to medications taken chronically for secondary prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the healthcare system despite the well-established benefits of prevention. We conducted a literature search to examine patient adherence to medications for secondary prevention of CVD—as evaluated by prescription refill data, electronic medication monitors, pill counts, and physiologic markers—to better identify an unmet need for measures to improve patient adherence to these therapies. Methods: English-language articles were obtained from the PubMed database using the following key words or combinations thereof “adherence,” “compliance,” “secondary prevention,” and “cardiovascular disease.” Publications that provided adherence data only for primary prevention, lacked data on medication adherence (e.g., focus on guideline adherence), emphasized quality-of-care outcomes, or focused on outcomes of acute interventions were excluded. Results: Multiple patient-, disease-, and treatment-related factors may contribute to poor adherence to treatment regimens, and therefore, a multifactorial approach will likely be needed to improve compliance with prescribed treatments for CVD. Although no magic bullet exists to assure full adherence, adherence programs coupled with patient counseling and education (inclusive of over-the-counter therapies), along with treatments that are less complex or avoid bothersome adverse effects, are more likely to be associated with successful outcomes. Conclusion: Given the burden of CVD to the community and the healthcare system, nonadherence to CVD-preventative medications such as aspirin remains a substantial area of unmet need and represents a key opportunity for the development of quality-of-care enhancement programs to improve health outcomes in this patient population.

AB - Aim: Suboptimal adherence to medications taken chronically for secondary prevention of cardiovascular disease (CVD, e.g., aspirin) continues to burden the healthcare system despite the well-established benefits of prevention. We conducted a literature search to examine patient adherence to medications for secondary prevention of CVD—as evaluated by prescription refill data, electronic medication monitors, pill counts, and physiologic markers—to better identify an unmet need for measures to improve patient adherence to these therapies. Methods: English-language articles were obtained from the PubMed database using the following key words or combinations thereof “adherence,” “compliance,” “secondary prevention,” and “cardiovascular disease.” Publications that provided adherence data only for primary prevention, lacked data on medication adherence (e.g., focus on guideline adherence), emphasized quality-of-care outcomes, or focused on outcomes of acute interventions were excluded. Results: Multiple patient-, disease-, and treatment-related factors may contribute to poor adherence to treatment regimens, and therefore, a multifactorial approach will likely be needed to improve compliance with prescribed treatments for CVD. Although no magic bullet exists to assure full adherence, adherence programs coupled with patient counseling and education (inclusive of over-the-counter therapies), along with treatments that are less complex or avoid bothersome adverse effects, are more likely to be associated with successful outcomes. Conclusion: Given the burden of CVD to the community and the healthcare system, nonadherence to CVD-preventative medications such as aspirin remains a substantial area of unmet need and represents a key opportunity for the development of quality-of-care enhancement programs to improve health outcomes in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84995446742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995446742&partnerID=8YFLogxK

U2 - 10.1111/1755-5922.12211

DO - 10.1111/1755-5922.12211

M3 - Review article

VL - 34

SP - 415

EP - 422

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 6

ER -